Shanghai Serum Bio-Technology Co. Ltd. A688163
▲ PositiveCapitalrelevance
Net profit rose 8.11% and dividend announced

Sailun Bio disclosed its 2026 interim report. In the first half, it achieved operating revenue of 104 million yuan, up 3.36% year on year. Net profit attributable to the parent company was 35.6513 million yuan, up 8.11% year on year. Basic earnings per share were 0.33 yuan. The company plans to distribute a cash dividend of 1.2 yuan, including tax, for every 10 shares.
Shanghai Serum Bio-Technology Co. Ltd. ANet profit rose 8.11% and dividend announced